I f your doctor has recommended chimeric antigen receptor (CAR) T-cell immunotherapy for large B-cell lymphoma (LBCL), you’ve likely already tried several standard treatments, and the cancer did not ...

MDX2003 targets CD19 and CD20 on B cells and CD3 and CD28 on T cells, enhancing antitumor activity and reducing antigen loss. The therapy's design limits cytokine release syndrome, showing improved ...

B-Cell Acute Lymphoblastic Leukemia for Adults: Causes, Symptoms, Diagnosis and Treatment: By Shreoshree Chakrabarty B-Cell Acute Lymphoblastic Leukemia (B-ALL) is a rare but aggressive form of ...

Promising advancements in CAR T-cell therapy for large B-cell lymphoma (LBCL) include potential new safety parameters, opportunities for precision care, and increased chances of achieving remission ...

Preclinical data showed enhanced anti-tumor activity and reduced cytokine release compared to conventional single-chain CAR T approaches -- Early clinical case from CELESTIAL-301 trial, the ...

The research is happening at Roswell Park Comprehensive Cancer Center.

The Sarah Cannon Transplant & Cellular Therapy Program at St. David's South Austin Medical Center is among a select group of organizations participating in a global clinical trial to examine the next ...

Metabolic tumor volume--a biomarker derived from PET imaging--can more accurately predict progression-free survival for large ...

SAN FRANCISCO, April 08, 2026 (GLOBE NEWSWIRE) -- Immusoft of CA, a clinical-stage biotechnology company pioneering engineered B cell therapies, today announced that it will present an invited ...

CAR T-cell therapy was first developed as a lymphoma treatment but has recently been applied to autoimmune diseases, primarily lupus, systemic sclerosis, and myositis. Up to this point, ulcerative ...